Content

Semaglutide Cost: Brand, Self-Pay and Compounded

Creator: Elena Marsh, Health Writer
Published: 2026-08-24

Wegovy lists near $1,350 a month and Ozempic near $1,040, while the manufacturer's own self-pay channel charges $349 and eligible Medicare beneficiaries now pay a $50 copay. Same molecule, four very different bills.

Elena Marsh, Health Writer August 24, 2026 6 min read

A woman sits by a window with both hands around a mug of tea in soft morning light

The short version

Wegovy's list price is about $1,350 a month and Ozempic's about $1,040; Novo Nordisk cuts both to $675 on 1 January 2027.
The manufacturer's own self-pay channel charges $349 a month for standard Wegovy and Ozempic pen doses, $399 for Wegovy HD 7.2 mg and $499 for Ozempic 2 mg.
Eligible Medicare Part D beneficiaries pay a $50 copay under the Medicare GLP-1 Bridge, a demonstration running from 1 July 2026 to 31 December 2027.
Cost or insurance issues were the primary reason 137 of 288 patients — 47.6% — stopped semaglutide or tirzepatide within a year in a 2025 Cleveland Clinic study.
Compounded is a different product, not a discounted brand: through Promise semaglutide is dispensed as a compounded medication, which is different from an FDA-approved product, and the formulation offered here is not FDA-approved.
A price is comparable only once you know whether the medical evaluation, the prescription, dispensing, shipping and follow-up sit inside it or are billed on top.

Semaglutide cost splits four ways in August 2026, and which route you take matters far more than the molecule. Brand-name Wegovy lists at roughly $1,350 a month and Ozempic at about $1,040. The manufacturer's own self-pay channel sells both at $349 a month at standard doses. Eligible Medicare Part D beneficiaries pay a flat $50 copay under a federal demonstration that opened on 1 July 2026. A compounded formulation prescribed through a telehealth network is priced differently again. Same active ingredient, four bills that are nowhere near one another.

The four semaglutide cost routes

List price. The wholesale acquisition cost is the sticker almost nobody pays, and it is about to move. On 24 February 2026 Novo Nordisk announced that from 1 January 2027 Wegovy, Ozempic and Rybelsus all drop to $675 a month: a cut of approximately 50% for Wegovy and 35% for Ozempic, which puts today's figures near $1,350 and $1,040.

Manufacturer self-pay. Novo also sells direct. As of August 2026 the standard self-pay price is $349 a month for Wegovy from 0.25 mg through 2.4 mg and $399 for Wegovy HD 7.2 mg; Ozempic is $349 at 0.25 mg, 0.5 mg and 1 mg, and $499 at 2 mg. People new to the savings offer pay $199 for the first two monthly fills of the two lowest doses, through 31 December 2026, and tablets price separately — $149 at 1.5 mg, $199 at 4 mg, $299 at 9 mg and 25 mg (NovoCare Pharmacy, retrieved August 2026). The January list-price cut does not touch these figures.

Compounded. A preparation made by a licensed U.S. compounding pharmacy against a prescription written for one patient, priced by the prescriber network rather than the manufacturer. The card below carries the current figure.

Route	Monthly cost	Notes
List price, Wegovy / Ozempic	~$1,350 / ~$1,040	Both fall to $675 on 1 Jan 2027
Self-pay, Wegovy pen	$349	$399 for HD 7.2 mg; $199 intro, first two fills
Self-pay, Ozempic pen	$349	$499 at 2 mg
Self-pay, Wegovy tablets	$149–$299	1.5 mg / 4 mg / 9 mg and 25 mg
Medicare GLP-1 Bridge	$50 copay	Eligible Part D, 1 Jul 2026 – 31 Dec 2027
Compounded (prescriber network)	see card	Priced by the service

Why insurance is the biggest variable

Coverage, not the sticker, decides most people's bill. Plans routinely cover semaglutide for type 2 diabetes and exclude it for weight management, which is why two people on the same molecule are quoted amounts an order of magnitude apart. Where a weight-management benefit does exist, it usually arrives with prior authorization, a documented BMI threshold, or a requirement to have tried something else first.

Manufacturer copay assistance narrows the gap only for people whose commercial plan already covers the drug; it does nothing about an outright exclusion, and government-insured patients are generally ineligible. That hole is why a self-pay channel and a compounded route exist at all.

The distance between production cost and market price is not small either. An economic evaluation in JAMA Network Open estimated sustainable cost-based prices for GLP-1 agonists at $0.75 to $72.49 a month (Barber et al., JAMA Netw Open 2024) — a modelling exercise, not a price anyone is offered, but it explains how one molecule can be sold at figures this far apart and still turn a profit.

What Medicare's $50 program actually covers

CMS opened the Medicare GLP-1 Bridge on 1 July 2026, a time-limited demonstration running through 31 December 2027 that gives eligible Part D beneficiaries certain GLP-1 drugs for a $50 copay (CMS).

The mechanics matter before you count on it. The Bridge sits outside the Part D benefit's coverage and payment flow, so the deductible does not apply, the $50 does not count towards your true out-of-pocket total, and no low-income subsidy is added on top. It is a demonstration with an end date, not a permanent benefit.

Semaglutide or tirzepatide, decided on price

Plenty of people reach this comparison as a budget question, not a clinical one. The two molecules are priced differently at every level — list, manufacturer self-pay and compounded — and the ranking is not the same at each, so which is cheaper depends on the route. We break the other side down in tirzepatide cost; the two are meant to be read together. Which molecule suits you is a prescriber's call, not a spreadsheet's, and what price can tell you is which one you could realistically sustain for a year.

What a compounded price actually buys

Through Promise, semaglutide is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here — semaglutide with vitamin B12 — is not FDA-approved. Compounded medications are not reviewed by the FDA for safety, effectiveness or quality.

That distinction is why the number is lower, so it is worth stating plainly. A compounded preparation is not a generic: a true generic must receive its own FDA approval and meet the agency's standards for sameness. What it buys is the molecule prepared by a licensed U.S. pharmacy against a prescription written for you — a real thing, and not a cheaper copy of the brand.

FDA's April 2026 compounding update notes that semaglutide appears on neither the 503B bulks list nor the drug shortage list, and sets out the 503A conditions — chiefly that a preparation is compounded for an individual patient on receipt of a prescription. A licensed provider may still prescribe a compounded formulation where the clinical and legal conditions are met — that decision is between you and your doctor. Compounded semaglutide covers the framework in full.

What a monthly price should include

A quoted price is only comparable once you know what sits behind it. At Promise the monthly figure covers the online medical evaluation by a licensed provider, the prescription where one is written, compounding and dispensing by a licensed U.S. pharmacy, temperature-controlled shipping, and follow-up check-ins.

Hold anything you compare against that list: a bare vial price with a consultation fee, a shipping charge and a refill fee bolted on is not the number it first appeared to be. How to get semaglutide prescribed sets out what the intake and review involve.

Cost is the top reason people stop

This is the part of the bill nobody prices in. In a Cleveland Clinic study of 288 adults with overweight or obesity and without type 2 diabetes who started injectable semaglutide or tirzepatide and stopped within the first year, 137 — 47.6% — gave cost or insurance-related issues as the primary reason. Inability to tolerate side effects accounted for 14.6% and supply problems for 11.8% (Gasoyan et al., Obesity 2025).

The persistence data points the same way. Among 1,911 patients starting any antiobesity medication in a large health system, 44% were still on treatment at three months, 33% at six and 19% at twelve; semaglutide had the highest one-year persistence of any category, at 40% (Gasoyan et al., Obesity 2024).

Together they change the practical question: a price you can hold for twelve months beats a lower one you abandon in month three, because trial results belong to the people who kept taking the drug.

Before you commit

Check whether your plan covers weight management specifically, not merely whether it covers semaglutide. Ask what a quoted price includes and what gets billed on top. Be clear about which of the four routes you are being offered; they are four different things at four different prices. And watch the calendar: the January 2027 list-price change matters most to anyone whose out-of-pocket cost is tied to list.

At Promise, a licensed provider reviews every request and prescribes only where semaglutide is appropriate. Not everyone qualifies, and nobody is charged for a prescription that is not written.

Common questions

How much does semaglutide cost per month?

It depends entirely on the route. Brand-name Wegovy's list price is about $1,350 a month and Ozempic's about $1,040, both dropping to $675 on 1 January 2027. The manufacturer's own self-pay channel charges $349 for standard pen doses, $399 for Wegovy HD 7.2 mg and $499 for Ozempic 2 mg. Eligible Medicare Part D beneficiaries pay a $50 copay through the Medicare GLP-1 Bridge.

What is the cheapest way to get semaglutide?

For most people it is not the retail pharmacy counter. Eligible Medicare Part D beneficiaries pay $50 a month under the GLP-1 Bridge demonstration through 31 December 2027. Everyone else is comparing the manufacturer's $349 self-pay price against a compounded preparation through a prescriber network, which is generally lower again. The lowest number is only meaningful once you know what it includes.

Does insurance cover semaglutide?

Often for type 2 diabetes, and often not for weight management. That split is the single biggest reason two people on the same molecule are quoted very different amounts. Where a weight-management benefit exists it usually requires prior authorization, a documented BMI threshold or evidence of prior attempts, and manufacturer copay assistance generally needs a commercial plan that already covers the drug.

Is compounded semaglutide an FDA-approved version of Wegovy?

No. FDA-approved versions of semaglutide exist — Wegovy, Ozempic and Rybelsus — but the compounded formulations offered here are not FDA-approved. A compounded preparation is made by a licensed pharmacy for an individual patient on a prescription and has not been through the review the branded products went through. It is a different product, not a discounted brand.

Why is compounded semaglutide cheaper than the brand?

Because it is a different product rather than a discounted one. An economic evaluation in JAMA Network Open estimated sustainable cost-based prices for GLP-1 agonists at $0.75 to $72.49 a month, so the raw molecule is not what sets brand pricing. What a compounded price buys is preparation by a licensed U.S. pharmacy against a prescription written for you, plus the clinical service around it.

What is the Medicare GLP-1 Bridge?

A time-limited CMS demonstration running from 1 July 2026 to 31 December 2027 that lets eligible Medicare Part D beneficiaries get certain GLP-1 drugs for a $50 copay. It operates outside the Part D benefit's payment flow, so the deductible does not apply, the $50 does not count towards true out-of-pocket costs, and no low-income subsidy applies. Prior authorization runs through a single central processor.

Does semaglutide cost more as the dose increases?

On the manufacturer's self-pay tiers, sometimes. Wegovy pen doses from 0.25 mg to 2.4 mg are all $349, with Wegovy HD 7.2 mg at $399; Ozempic steps from $349 up to $499 at 2 mg; the Wegovy tablet runs $149, $199 or $299 by strength. A flat monthly plan through a prescriber network does not step with dose, which matters if you expect to titrate.